ArticleJournal of molecular neuroscience : MN2009
Characterization of Meteorin--an evolutionary conserved neurotrophic factor.
Article in Journal of molecular neuroscience : MN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes Mellitus
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Effects of intracerebroventricular Metrnl administration on the hypothalamic-pituitary-testicular axis in male rats.Molecular biology reports · 2026Article
- Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments.GeroScience · 2025Review
- Article
- Meteorin-β: A Novel Biomarker and Therapeutic Target on Its Way to the Regulation of Human Diseases.International journal of molecular sciences · 2025Review
- Bacteriological profile of diabetic foot ulcers and analysis of serum meteorin levels.Molecular biology reports · 2025Article
- The accumulation of harmful genes within the ROH hotspot regions of the Tibetan sheep genome does not lead to genetic load.BMC genomics · 2025Article
- A pan-cancer analysis of the association of METRN with prognosis and immune infiltration in human tumors.Heliyon · 2024Article
- Human Pluripotent Stem Cell-Derived Astrocyte Functionality Compares Favorably with Primary Rat Astrocytes.eNeuro · 2024Article
- Meteorin Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Mice.The journal of pain · 2023Article
- Decreased serum interleukin-41/Metrnl levels in patients with Graves' disease.Journal of clinical laboratory analysis · 2022Article
- Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data.Frontiers in neurology · 2022Article
- Progress of Adipokines in the Female Reproductive System: A Focus on Polycystic Ovary Syndrome.Frontiers in endocrinology · 2022Review
- Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.Journal of clinical medicine · 2021Article
- Over expression of METRN predicts poor clinical prognosis in colorectal cancer.Molecular genetics & genomic medicine · 2020Article
- Article
- Metrnl: a secreted protein with new emerging functions.Acta pharmacologica Sinica · 2016Review
- Over-Expression of Meteorin Drives Gliogenesis Following Striatal Injury.Frontiers in cellular neuroscience · 2016Article
- Meteorin is upregulated in reactive astrocytes and functions as a negative feedback effector in reactive gliosis.Molecular medicine reports · 2015Article
- METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages.Clinical immunology (Orlando, Fla.) · 2015Article
- Maternal Serum Meteorin Levels and the Risk of Preeclampsia.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth factors control cellular growth, proliferation, and differentiation and may have therapeutic applications. In this study, we focus on Meteorin which is a member of a largely uncharacterized evolutionary conserved two-member growth factor family. Our analysis shows that Meteorin is expressed in the central nervous system both during development and in adult mice. Detailed immunohistological analysis of the adult mouse brain reveals that Meteorin is highly expressed in Bergmann glia and in a few discrete neuronal populations residing in the superior colliculus, the ocular motor nucleus, the raphe and pontine nuclei, and in various thalamic nuclei. In addition, low levels of Meteorin is found in astrocytes (S100beta+, OX42-) distributed ubiquitously throughout the brain. Meteorin was cloned and recombinant protein purified allowing N-terminal sequencing and mass spectrometric analysis showing that Meteorin is secreted as an unmodified monomer. This form is bioactive as it induces neurite outgrowth from dorsal root ganglions in vitro. Intrastriatal protein injection and lentiviral studies in vivo showed that Meteorin is a highly diffusible molecule in the brain and cellular uptake is apparent in specific populations which may carry the receptor. In summary, we provide a comprehensive expression analysis and have made and thoroughly validated molecular tools to help investigate the therapeutic potential of Meteorin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.